Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.78 |
| ▸ | PPARG | P37231 | 4/20 | 0.76 |
| ▸ | BAG3 | O95817 | 1/20 | 0.68 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8188594 | 0.88 | AKR1B1 (1.00) | AKR1B1CISD1POLBPABPC1 | |
| SCHEMBL8188593 | 0.88 | AKR1B1 (1.00) | AKR1B1CISD1POLBPABPC1 | |
| SCHEMBL21783144 | 0.87 | PPARG (0.77) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL22092306 | 0.86 | PPARG (1.00) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL21783143 | 0.86 | PPARG (1.00) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL28374629 | 0.85 | PPARG (0.81) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL21783127 | 0.85 | PPARG (0.81) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL20534277 | 0.83 | ALDH1A1 (0.76) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL21783131 | 0.83 | BAG3 (0.72) | AKR1B1PPARGBAG3ALDH1A1MEN1 | |
| SCHEMBL20534278 | 0.83 | ALDH1A1 (0.76) | AKR1B1PPARGBAG3ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| CN-110621315-A | Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelic acid pathway | 拉筹伯大学 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | AKR1B1 225/4885PPARG 3668/4885BAG3 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.